Trial reportJournal of cosmetic dermatology2026
An Open-Label Study to Assess the Efficacy and Tolerability of a Multifunctional, 10-Peptide Face and Neck Serum to Address Skin Quality.
Trial report in Journal of cosmetic dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is increasing patient demand for improved skin quality and the desire to achieve rejuvenated skin and improve self-confidence.
aimsThe objective of this 12-week study was to assess changes in skin quality and subject satisfaction after using a novel anti-aging 10-peptide serum (Pep Up Collagen Boost Face & Neck Serum; Colorescience Inc., Carlsbad, CA). PATIENTS/
methodsHealthy adult subjects seeking facial and neck skin rejuvenation (N = 48) were divided into two groups. Group A included subjects not currently using prescription, medical grade, advanced, or physician-dispensed skincare products and Group B included subjects who currently were using such products. Subjects in both groups applied the anti-aging peptide serum twice daily as part of their daily skincare routine for 12 weeks and were evaluated after 4, 8, and 12 weeks of treatment. Improvements in Global Skin condition and other parameters associated with skin quality were assessed by three investigators.
resultsBy Week 12, 89.6% of subjects showed clinical improvement (p < 0.01), with most (52%) achieving moderate-to-marked global improvement. Both groups had median global scores of 3.0, with similar mean scores (Group A, 2.6; Group B, 2.8). Subjects in both groups indicated improvements in global scores (Group A, 91.7%; Group B, 87.5%) and most subjects in both groups demonstrated marked improvements from baseline (54.2% and 50.0%). The product was well-tolerated and subject satisfaction was high.
conclusionsThe twice-daily application of a novel anti-aging 10-peptide serum restores several markers of facial and neck skin quality that were incremental to basic skincare routines and professional skincare regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.